Business
Publication of Annual Report and Notice of AGM
Publication of Annual Report and Notice of AGM.
About this update from Oxford Biodynamics Plc
[{"type":"text","content":"\n \nRNS Number : 6492A Oxford BioDynamics PLC 23 January 2020 \n\n23 January 2020\n \nOxford BioDynamics Plc\n(\"OBD\" or the \"Company\" and, together with its subsidiaries, the \"Group\")\n \nPublication of 2019 Annual Report and Accounts and Notice of AGM\n \nOxford BioDynamics Plc (AIM: OBD), a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, today announces that copies of its annual report and accounts for the year ended 30 September 2019 (incorporating the Notice of Annual General Meeting) (\"Annual Report\") have been posted to shareholders. An electronic copy of the Annual Report will be available on its website at www.oxfordbiodynamics.com, within the Investor Relations section.\n \nNotice of Annual General Meeting\nThe Company's Annual General Meeting will be held at The Kloppenberg Room, Cohen Quad, Exeter College, Walton Street, Oxford, OX1 2HE, on 20 March 2020 at 11.00 am.\n \n-ENDS-\n \nFor further details please contact:\n \n\n\n\nOxford BioDynamics Plc \nChristian Hoyer Millar, CEO \nPaul Stockdale, CFO\n \n\n\n+44 (0)1865 518910\n\n\n\n\nShore Capital\nNominated Advisor and Broker\nStephane Auton\nEdward Mansfield\n\n\n+44 (0)20 7408 4090 \n\n\n\n\n \nFTI Consulting \nFinancial Public Relations Adviser\nNatalie Garland-Collins\n\n\n+44 (0)20 3727 1000 \n\n\n\n \nNotes for Editors\n \nAbout Oxford BioDynamics Plc\n \nOxford BioDynamics Plc (AIM: OBD) (\"Oxford BioDynamics\") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. \n \nThe Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. \n \nIn particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables...